Sean E Collins

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Kenneth H. Mayer, Jean‐Michel Molina, Melanie Thompson et al. · The Lancet · 2020 · 424 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

David A. Wohl, Yazdan Yazdanpanah, Axel Baumgarten et al. · The Lancet HIV · 2019 · 165 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens et al. · The Lancet HIV · 2019 · 143 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials

Chloe Orkin, Edwin DeJesus, Paul E. Sax et al. · The Lancet HIV · 2020 · 136 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Gender inequality and HIV transmission: a global analysis

Eugene T Richardson, Sean E Collins, Tiffany H. Kung et al. · Journal of the International AIDS Society · 2014 · 132 citations · Full text

Social Sciences, Demography, Population Health Sciences +16